Table 1.

Baseline and Week 12* characteristics of the included patients. Values are mean ± SD unless otherwise specified.

CharacteristicsInfliximabEtanerceptAll
Patients, n431760
Male, n (%)29 (67)15 (88)44 (73)
Age, yrs38.0 ± 7.736.0 ± 6.637.5 ± 7.4
Disease duration, yrs14.0 ± 8.613.1 ± 7.513.8 ± 8.3
HLA-B27–positive, n (%)37 (88)14 (82)51(85)
mSASSS11.2 ± 16.410.9 ± 15.511.1 ± 16.1
BaselineWeek 12BaselineWeek 12BaselineWeek 12
BASDAI6.3 ± 1.43.0 ± 1.76.5 ± 1.22.6 ± 2.26.4 ± 1.32.9 ± 1.8
BASFI5.2 ± 1.93.1 ± 1.95.3 ± 1.92.9 ± 2.65.2 ± 1.93.1 ± 2.1
BASMI3.4 ± 2.12.7 ± 1.93.9 ± 2.02.1 ± 2.03.5 ± 2.02.5 ± 1.9
CRP, mg/l23.7 ± 18.24.8 ± 3.023.0 ± 19.35.9 ± 2.423.5 ± 18.35.1 ± 2.8
  • * Week 12 data were used for clinical variables as baseline in the longitudinal analysis to eliminate the initial effect of TNF blockers. mSASSS: modified Stoke Ankylosing Spondylitis Spine Score; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; BASMI: Bath Ankylosing Spondylitis Metrology Index; CRP: C-reactive protein.